Kornimate/medical-research-clean huggingface dataset:
autophagy in paediatric crohn's disease

Conditions: Crohn Disease; Pediatric Crohns Disease

Summary: crohn's disease is a multifactorial complex disease resulting in a between microbiota and immune system. indeed, gwas (genome-wide association studies) association study pinpointed polymorphisms as genes susceptibility on more than 200 loci. among them genes coding for proteins involved in autophagy machinery (i.e: atg16l1, irgm et ndp52). autophagy is a ubiquitous intracellular mechanism mandatory for protein and microorganism recycling. so far, the role of autophagy in gut inflammation and intestinal homeostasis in crohn's disease patients is partially understand. then, investigators plan to evaluate, on native cells, the autophagic flux in pediatric patients suffering of a crohn's disease compare to controls.


Eligibility criteria:
inclusion criteria: for crohn's disease group : * age between 6 and 17 inclusive * patients with a weight \> 25 kg at the time of inclusion * patients with crohn's disease requiring ileocolonoscopy (diagnosis or follow-up) * mild to severe crohn's disease consistent with pcdai disease activity score * patients on nutritional therapy (modulen/modulife), corticosteroids, salicylic derivatives, immunosuppressants, biotherapies (anti-tnf, vedolizumab and ustekinumab) or without treatment * consent form signed by the patient or the holder(s) of parental authority. * affiliation to a social security scheme or beneficiaries of a similar scheme. for control group: * between 6 and 17 years old included * presenting a weight \> 25 kg at the time of inclusion * without a diagnosis of crohn's disease * requiring evaluation by ileoendoscopy * consent form signed by the patient or the holder(s) of parental authority. * affiliation to a social security scheme or beneficiaries of a similar scheme. exclusion criteria: * refusal to participate in the protocol * intercurrent infection * ongoing antibiotic treatment * patient involved in another interventional study protocol including an exclusion period still in progress at pre-inclusion * pregnant, parturient or breastfeeding women (on questioning) * persons deprived of their liberty by a judicial or administrative decision * persons subject to psychiatric care * persons admitted to a health or social establishment for purposes other than research

Keywords: crohn's disease autophagy polymorphism
does maternal instruction prevent kernicterus in nigeria?

Conditions: Kernicterus

Summary: this study examines (a) whether introduction of public, health provider, and maternal education about risks of jaundice will decrease the occurrence of abe compared with baseline prevalence (before-after design) or (b) whether antenatal or postpartum instruction to mothers will decrease the incidence of abe compared with those who did not received instruction (concurrent opportunistic controls in phase 2).

this 2 phase study first determines the prevalence of acute bilirubin encephalopathy (abe) among newborns admitted for treatment of jaundice at 5 regional centers in nigeria and identifies social/behavioral/medical factors associated with abe. information gained in phase 1 identified high risk sub-populations and guided selection of instructional materials for phase 2. core data sheets submitted monthly by participating centers included clinical data, demographic information, number of antenatal clinic visits, birth place (hospital, clinic, home) and attendant, distance from care centers and reasons for delay, if any, in seeking care. receipt of jaundice instruction by mothers is self-reported. statistical analysis includes chi square and logistic regression analysis of risk factors. sample size: 1,000 subjects in each phase are required to demonstrate a 20% decrease in disease prevalence (baseline abe incidence anticipated to be 15% of jaundiced babies) at 95% confidence level.

Eligibility criteria:
inclusion criteria: * newborn infant receiving treatment for neonatal jaundice exclusion criteria: * non-viable premature infants * severe congenital defects. * postnatal age greater than 21 days
events preceding interstitial cystitis (epic)

Conditions: Cystitis, Interstitial

Summary: epic is a case/control study that seeks to identify the risk factors for interstitial cystitis by comparing the experiences and medical histories of 400 women who recently developed ic with 400 similar people who do not have the disease.

this project is a systematic, national study of incident ic cases and controls matched by age and gender. by telephone interview and medical record review, we compare exposures of cases and controls seeking significant differences which may be risk factors for ic. this cohort of incident ic cases will initiate a natural history study of the disease. specific aim 1. to test the hypothesis that certain features that precede onset of ic symptoms, e.g., bacterial cystitis, distinguish ic cases from controls matched for age and gender, and may be risk factors for the disease. specific aim 2. to test the hypotheses that patients with ic have higher prevalences of certain non bladder syndromes, e.g., irritable bowel syndrome, than do controls matched for age and gender. specific aim 3. to test the hypothesis that urine apf, hb egf, and/or egf are sensitive and specific diagnostic markers for ic in patients with symptoms of ÿ12 months. specific aim 4. to test the hypotheses that, in an incident cohort, patients with ic have remissions and that certain clinical features, e.g., bacterial cystitis at disease onset, are prognostic factors for remissions.

Eligibility criteria:
inclusion criteria: female adults(18 and over) who have had symotoms of ic for 12 months or fewer - exclusion criteria: males,children, those who do not have symptoms of ic or those who have had symtoms for greater than 12 months. -

Keywords: cystitis, interstitial case-control studies risk factors
lung nodule characterization by artificial intelligence techniques

Conditions: Incidental Lung Nodule

Summary: management of incidental lung nodule is difficult and mainly based on simple morphometric characteristics such as maximum size and shape. radiomics could play a role in simplifying this management by orientating towards a benign or a malignant origin, by comparing advanced characteristics to a large database of lung nodules. the primary purpose is to evaluate the performances of a novel tool based on radiomics to characterize incidental lung nodules, discovered on computed tomography. the secondary objectives are: * to evaluate the variation in the performances of the software based on various technical aspects of the ct, such as radiation dose, reconstruction algorithm, type of scanner,... * to compare the performances of this software to those of expert readers, * to analyze the potential impact of this software on patient's management.


Eligibility criteria:
inclusion criteria: * adult patient (at least 18 years old); * with a chest ct acquired between jan 1 2012 and oct 1 2018 at the strasbourg university hospital; * ct being available over the pacs and exhibiting at least one lung nodule; * patient having given its authorization for the exploitation of his medical data for this research. exclusion criteria: * patient having expressed direct opposition to participation in this study; * patient under juridical protection; * patient under tutelage or guardianship.

Keywords: solitary pulmonary nodule multidetector computed tomography artificial intelligence
pharmacokinetics and pharmacodynamics study of gemcabene in healthy volunteers

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to evaluate the multiple-dose pharmacokinetic characteristics and pharmacologic activity of gemcabene.


Eligibility criteria:
inclusion criteria: * good health as determined by medical history, physical examination, electrocardiogram (ecg), vital signs, and laboratory assessments * body weight: 60-100 kg (desirable) exclusion criteria: * use of any medication not considered acceptable by the clinical investigators during the 14-day period before the start of the study (day 1) ; * donation of a unit of blood or participation in a study of investigational or marketed drugs during the 30-day period before the start of the study (day 1); * if female, of childbearing potential or lactating; * history of significant reaction to any fibrate lipid-lowering agent; and * significant urine collection of any drug which could interfere with the study

Keywords: pharmacokinetics lipid regulator
68ga-nota-rm26 pet/ct in breast tumor patients

Conditions: Breast Tumor

Summary: this is an open-label positron emission tomography/computed tomography(pet/ct) study to investigate the diagnostic performance and evaluation efficacy of 68ga-nota-rm26 in breast tumor patients. 1.85 mbq per kilogram body weight of 68ga-nota-rm26a will be injected intravenously. visual and semiquantitative method will be used to assess the pet/ct images.

the gastrin-releasing peptide receptor (grpr), also known as bombesin receptor subtype ii (bb2), is a member of the g protein-coupled receptor family of bombesin receptors. grpr is over-expressed in various types of human tumors including breast cancer. rm26, a grpr antagonist with high affinity, was discovered by peptide backbone modification of bombesin analogues.to target gastrin-releasing peptide receptor in neoplastic cells of human breast cancer, peptide nota-rm26 was synthesized with a peg3 linker between nota and rm26, and then labeled with 68ga. an open-label whole-body pet/ ct study was designed to assess its clinical diagnostic value in patients with breast tumor.

Eligibility criteria:
inclusion criteria: * patients in suspicion of breast cancer by mammography or ultrasonography,and being able to provide basic information and sign the written informed consent form exclusion criteria: * the exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study, and undergoing any preceding local or systemic therapies that might interfere with grpr binding
the effect of scalp block on surgical pleth index(spi) during a mayfield head-holder insertion

Conditions: Pain

Summary: it is a randomized control trial to compare the surgical plethysmographic index (spi) response during a mayfield head-holder insertion in neurosurgical patients who receive a scalp block versus those who do not receive the scalp block after induction of anesthesia with propofol with fentanyl and intubation with cis-atracurium.

study design is a randomized controlled trial participants include adult neurosurgical patients scheduled to have a mayfield head-holder insertion for supratentorial craniotomy intervention is a scalp block prior to a mayfield head holder insertion. comparison is 'no scalp block' outcome is surgical plethysmographic index (spi) responses during/after a mayfield head holder insertion sample size includes 30 cases (15 cases per arm) the eligible neurosurgical patients will be randomly allocated, by a concealed randomization process, to receive or not to receive a scalp block after induction and intubation with propofol/fentanyl and cisatracurium. surgical plethysmographic index, direct arterial blood pressure, heart rate (eeg), end tidal carbondioxide, bispectral/entropy (40-60) will be recorded every one minute before/after induction and intubation, before/after the scalp block, and before/after the mayfield head-holder insertion. the mayfield head-holder insertion will be performed by a neurosurgeon who will be blinded to the allocated groups. data analysis is performed to compare the change of spi during and after the mayfield head-holder insertion from the baseline in both groups by using repeated measure anova at the significant level of 0.05.

Eligibility criteria:
inclusion criteria: * patients will receive a mayfield head-holder insertion for supratentorial craniotomy exclusion criteria: * history of chronic hypertension, diabetes mellitus (dm), coronary heart diseases * receiving beta blockers * bmi \> 30 * coagulopathy * severe liver and renal diseases

Keywords: scalp block, surgical peth index
effect of high levels of oxygen and smoking on the lungs in human volunteers

Conditions: Healthy Volunteers

Summary: patients with lung disease experiencing difficulty breathing can be treated with oxygen therapy. this involves the delivery of "extra" oxygen by a face-mask or through small tubes placed in the nose called nasal prongs. this extra oxygen can have concentrations as high as 100% pure oxygen. the concentration of oxygen in normal air is only 21%. the high concentration of oxygen can help to provide enough oxygen for all of the organs in the body. unfortunately, breathing 100% oxygen for long periods of time can cause changes in the lungs, which are potentially harmful. researchers believe that by lowering the concentration of oxygen therapy to 40% patients can receive it for longer periods of time without the risk of side effects. this study is designed to evaluate the effects of oxygen therapy at 100% and 40% for 12 18 hours on the lungs of normal volunteers. results of this study will help to determine if levels of oxygen therapy currently accepted as being "safe" may actually be damaging to the lungs.

stress such as high oxygen or inflammation can result in damage to proteins by processes such as oxidation or alternative regulation of signaling pathways by post-translational modification of proteins (e.g., phosphorylation). delivery of oxygen in high concentrations to the lungs can result in damage, which is mediated in large part by reactive oxygen species. inflammation can result in activation of intracellular signaling pathways. this study will evaluate modification of proteins and nucleic acids in bronchoalveolar lavage fluid, bronchial epithelial cells, and peripheral blood of individuals exposed to oxygen or who are smokers. in doing so, it will determine the effects of hyperoxia or inflammation on the lung.

Eligibility criteria:
* inclusion criteria: history - good overall health without history of recent (within 3 months) acute disease; physical examination within normal limits; laboratory evaluation; including complete blood count (cbc), serum electrolyte determinations, clotting times, chest x-ray, pulmonary function testing, and an electrocardiogram (ekg) - within normal limits; non-smokers defined as having never smoked or not smoked in the past 2 years; smokers defined as moderate (1 pack per day for 3+ years) or heavy (1-2 packs for 10+ years); subjects must be willing to make the time commitment necessary for the study. exclusion criteria: any study subject who does not fulfill the criteria for eligibility. individuals with a history of allergy or adverse reactions to atropine or any local anesthetic; individuals testing positive for the human immunodeficiency virus or hepatitis virus; individuals on chronic medications or currently receiving medications; pregnant or lactating individuals, since the effects of hyperoxia on the fetus are unclear.

Keywords: oxygen bronchoalveolar lavage dna repair carbonyl groups serum human volunteers
paracervical block during ii-trimester abortion

Conditions: Second Trimester Medical Abortion

Summary: paracervical blockage can reduce severe pain during second trimester induced medical abortion.


Eligibility criteria:
inclusion criteria: * women who request second trimester medical abortion (13-22 weeks gestation according to ultrasound) * 18 years of age or older * able to understand and communicate in swedish * able to understand the study related information and willing to give her * informed consent to participation in the study exclusion criteria: * known allergy to bupivakain or related substances

Keywords: medical abortion second trimester para cervical blockage pain management
the safety and efficacy of autologous transfusion in spinal surgery for lung cancer with spinal metastasis

Conditions: Spinal Metastases; Blood Transfusion Complication; Lung Cancer; Surgery; Autologous Blood Transfusion

Summary: the goal of this single-center prospective randomized controlled trial is to test and compare the safety and effectiveness of autologous blood transfusion in spinal surgery for lung cancer spinal metastases. the main questions it aims to answer are: * does autologous blood transfusion increase the incidence of new metastases? * does autologous blood transfusion affect postoperative hemoglobin levels and the number of circulating tumor cells in the blood? * can autologous blood transfusion reduce the rate of allogeneic transfusion during and after surgery for spinal metastases?

in this study, participants underwent standard open spinal decompression surgery, and when blood transfusion was needed, autologous blood transfusion or allogeneic blood transfusion was used. participants will be patients with lung cancer spinal metastases. investigators will use flow cytometry, immunohistochemistry, and tumor cell culture methods to measure the number of circulating tumor cells in the blood before and after autologous blood transfusion. investigators will compare participants who receive autologous blood transfusion with those who do not to observe if there are differences in: * the incidence of new metastases * the rate of allogeneic transfusion during and after surgery * postoperative hemoglobin levels * the number of circulating tumor cells in the blood * the cost associated with transfusion

Eligibility criteria:
inclusion criteria: * the age range is 18-75 years old; * the pathological diagnosis was lung cancer and spinal metastatic tumor; * expected survival \> 3 months, can tolerate surgery; * unstable spine; and/or spinal cord nerve compression, nerve function; progressive decline, palliative spinal open decompression surgery * patients with intraoperative/postoperative hb\<90 g/l or other conditions requiring blood transfusion exclusion criteria: * serious heart dysfunction or heart failure, diagnosed blood system diseases, coagulation disorders; * severe renal insufficiency or need hemodialysis treatment; * sepsis or septicemia; * unable to obtain consent from the patient or family.
carbon dioxide laser treatment in burn-related scarring

Conditions: Burns Scarring

Summary: this study evaluates the effect effect of ablative fractional co2 laser (afco2l) on burns scar appearance and dermal architecture at 6 weeks and up to 3-years post-treatment. half of the scar will receive afco2l and half the scar will receive standard care.

ablative fractional co2 laser (afco2l) is emerging as a promising scar treatment for burns patients. fractionated delivery of co2 laser treatment leaved columns of undamaged skin to quickly re-epithelialize and has reduced the previously higher risk profile of unfractionated ablative laser delivery in terms of permanent pigmentation changes, higher rates of infection and scarring. the exact mechanisms of co2 laser action are still unclear, but likely involve a combination of macroscopic ablative fenestration, microscopic thermal collagen alteration and molecular profile alterations. use of afco2l for scar management is increasing amongst burn clinicians; consensus opinion and several large series have demonstrated safe and effective result, however robust randomised controlled evidence for the efficacy of co2 laser on burns scarring is still lacking.

Eligibility criteria:
inclusion criteria: * minimum burn injury scar area of 10x10cm * vancouver scar scale (vss) score of \>5 * ≥6 months following injury * patient age 18+ years exclusion criteria: * current pregnancy or lactation * patients unable to consent (dementia or another cognitive dysfunction) * non-english-speaking patients * scars on the face or hand (these anatomical areas were considered to be of significant aesthetic and functional importance and thus excluded from the trial )

Keywords: co2 laser ablative fractional laser
development of ultra-low dose ct based screening for aortic aneurysms

Conditions: Aortic Aneurysm, Thoracic; Aortic Aneurysm, Abdominal

Summary: the primary objective of this research project is development and validation of a new, non-contrast gated aortic (ncga) computer tomography scan algorithm for screening of aortic aneurysm in the chest and abdomen in at risk patients. this study would initially be performed in patients with a known aneurysm and done in addition to their indicated surveillance ct scan.

study design: patients who agree to enroll in the study will get the ncga study as well as a routine non-contrast computed tomography of chest/abdomen/pelvis within one year following recruitment at the patient's convenience. no follow-up will be required, but any clinically relevant findings on the testing will be communicated to the pcp through epic in-basket. urgent findings, as determined by the primary investigator, will also result in a direct communication with the pcp. it is expected that any such findings will also be seen on the standard and clinically indicated ct which they are also undergoing, and so "new or unique" findings on the study ncga test are not expected to occur. the final study visit will be the day of participation. study design: patients who agree to enroll in the study will get the ncga study as well as a routine non-contrast computed tomography of chest/abdomen/pelvis within one year following recruitment at the patient's convenience. no follow-up will be required, but any clinically relevant findings on the testing will be communicated to the pcp through epic in-basket. urgent findings, as determined by the primary investigator, will also result in a direct communication with the pcp. it is expected that any such findings will also be seen on the standard and clinically indicated ct which they are also undergoing, and so "new or unique" findings on the study ncga test are not expected to occur. the final study visit will be the day of participation. study procedures: one visit to complete one (1) non-contrast (no "dye"/contrast material will be injected) computed tomography (ct) scan of the chest, abdomen and pelvis. this visit will occur within one year following recruitment, scheduled at the patient's convenience. this one visit represents the totality of study participation for each participant. study duration: for each individual, participation is only over one day - the day of the patient's non-contrast ct scan. no early termination visits or unscheduled visits apply. the anticipated duration to complete enrollment of all participants is 1 year. following completion of the study, the study team is planning for an interim period of 6 months for discussion and planning for future projects.

Eligibility criteria:
inclusion criteria: * adult patients who carry the diagnosis of thoracic aortic aneurysm, aortic dissection, or abdominal aortic aneurysm and require ct imaging to evaluate the pathology exclusion criteria: * current pregnancy
study to evaluate safety, efficacy and tolerability of clobetasol propionate for chronic hand dermatitis

Conditions: Hand Dermatosis

Summary: the purpose of the study is to assess the safety, efficacy and tolerability of clobetasol propionate foam in subjects with chronic dermatitis.

the study is being conducted in order to obtain safety, efficacy and tolerability data for clobetasol propionate foam in the treatment of chronic dermatitis. the subjects must have mild to moderate disease based on the investigator's assessment at baseline.

Eligibility criteria:
inclusion criteria: * subjects 18 years of age or older, with diagnosis of chronic dermatitis, able to complete the study and comply with study instructions. * female subjects of childbearing potential must have a negative pregnancy test. sexually active women of childbearing potential participating in the study must have been using a medically acceptable form of contraception exclusion criteria: * use of systemic corticosteroid and/or other prohibited medications within 4 weeks of the baseline visit. * use of topical corticosteroid therapy and/or other prohibited topical medications within 2 weeks prior to the baseline visit

Keywords: dermatosis, dermatitis, dry skin, irritated skin